JP2009521406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009521406A5 JP2009521406A5 JP2008542752A JP2008542752A JP2009521406A5 JP 2009521406 A5 JP2009521406 A5 JP 2009521406A5 JP 2008542752 A JP2008542752 A JP 2008542752A JP 2008542752 A JP2008542752 A JP 2008542752A JP 2009521406 A5 JP2009521406 A5 JP 2009521406A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- compound
- use according
- immunosuppressive
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 17
- 102000038129 antigens Human genes 0.000 claims 17
- 108091007172 antigens Proteins 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 14
- 244000005700 microbiome Species 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 230000002519 immonomodulatory Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 230000001506 immunosuppresive Effects 0.000 claims 8
- 230000003248 secreting Effects 0.000 claims 7
- 102000004965 antibodies Human genes 0.000 claims 5
- 108090001123 antibodies Proteins 0.000 claims 5
- 230000028993 immune response Effects 0.000 claims 5
- 235000013305 food Nutrition 0.000 claims 4
- 239000002417 nutraceutical Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drugs Drugs 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 239000007937 lozenge Substances 0.000 claims 3
- 241000193798 Aerococcus Species 0.000 claims 2
- 241000206594 Carnobacterium Species 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 241000194033 Enterococcus Species 0.000 claims 2
- 102100004572 FLT3LG Human genes 0.000 claims 2
- 101710022257 FLT3LG Proteins 0.000 claims 2
- 206010018651 Graft versus host disease Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 101700046422 IFNA Proteins 0.000 claims 2
- 108090000174 Interleukin-10 Proteins 0.000 claims 2
- 102000003814 Interleukin-10 Human genes 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- 241000186660 Lactobacillus Species 0.000 claims 2
- 229940039696 Lactobacillus Drugs 0.000 claims 2
- 241000194036 Lactococcus Species 0.000 claims 2
- 241000192132 Leuconostoc Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- YDXZSNHARVUYNM-UHFFFAOYSA-N N-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxybenzamide Chemical compound CCOC1=CC=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 YDXZSNHARVUYNM-UHFFFAOYSA-N 0.000 claims 2
- 241000202223 Oenococcus Species 0.000 claims 2
- 241000192001 Pediococcus Species 0.000 claims 2
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 2
- 229940081969 Saccharomyces cerevisiae Drugs 0.000 claims 2
- 241000194017 Streptococcus Species 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 241000207194 Vagococcus Species 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- -1 boluses Substances 0.000 claims 2
- 238000002651 drug therapy Methods 0.000 claims 2
- 208000006673 Asthma Diseases 0.000 claims 1
- 208000005783 Autoimmune Thyroiditis Diseases 0.000 claims 1
- 206010009839 Coeliac disease Diseases 0.000 claims 1
- 206010067647 Delivery Diseases 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000002009 allergen Effects 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000000961 alloantigen Effects 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
Claims (17)
- 哺乳動物において免疫寛容を誘導するためまたは抗原に対する望まれない免疫反応により起こる疾患を処置するための薬剤、メディカルフードまたはニュートラシューティカルを調製するための、抗原と組み合わせた免疫モデュレーション化合物分泌微生物の使用。
- 哺乳動物において抗原に対する望まれない免疫反応により起こる疾患に関与する疾患もしくは障害を処置、予防および／もしくは緩和するための、または免疫寛容を誘導するための薬剤、メディカルフードまたはニュートラシューティカルを調製するための、組成物の使用であって、該組成物が、少なくとも免疫モデュレーション化合物分泌微生物および抗原を含むことを特徴とする使用。
- 抗原が、アレルゲン、アロ抗原、セルフ抗原または自己抗原である、請求項１または２記載の使用。
- 抗原が、アレルギー性喘息、多発性硬化症、Ｉ型糖尿病、自己免疫性ブドウ膜炎、自己免疫性甲状腺炎、自己免疫性重症筋無力症、関節リウマチ、食物アレルギーまたはセリアック病の誘導に関与する、請求項１から３のいずれか記載の使用。
- 直腸デリバリー、頬デリバリー、肺デリバリー、眼デリバリー、鼻デリバリー、膣デリバリーおよび経口デリバリーからなる群より選択される粘膜デリバリーのための、請求項１から４のいずれか記載の使用。
- 抗原および／または免疫モデュレーション化合物発現微生物が、噴霧剤、カプセル剤、エアロゾル、口中錠（lozenge）、ボーラス、錠剤、サシェ、液剤、懸濁剤、乳剤またはトローチ剤によりデリバリーされる、請求項１から５のいずれか記載の使用。
- 免疫モデュレーション化合物が、免疫抑制サイトカインまたは抗体であり、免疫抑制サイトカインが、ＩＬ−４、ＩＬ１０、ＩＦＮ−α、Ｆｌｔ３Ｌ、ＴＧＦβおよびＲＡＮＫ−Ｌからなる群より選択され、そして免疫抑制抗体が、抗ＩＬ−２、抗ＩＬ−１２および抗ＩＦＮ−γ抗体からなる群より選択される、請求項１から６のいずれか記載の使用。
- 微生物が、Lactobacillus、Leuconostoc、Pediococcus、Lactococcus、Streptococcus、Aerococcus、Carnobacterium、Enterococcus、Oenococcus、Teragenococcus、Vagococcus、WeisellaおよびSaccharomyces cerevisiaeからなる群より選択される、請求項１から７のいずれか記載の使用。
- 抗原および／または免疫モデュレーション化合物分泌微生物が、免疫抑制サイトカインの産生を刺激する化合物、好ましくはコレラ毒素Ｂサブユニットをさらに含む、請求項１から８のいずれか記載の使用。
- 抗原および／または免疫モデュレーション化合物分泌微生物が、少なくとも１０フェムトグラム/日から１００mg/日の用量でデリバリーされる、請求項１から９のいずれか記載の使用。
- 免疫モデュレーション化合物分泌微生物を抗原と組み合わせて含む組成物であって、免疫モデュレーション化合物が、免疫抑制化合物または抗体であり、免疫抑制化合物が、ＩＬ−４、ＩＬ１０、ＩＦＮ−α、Ｆｌｔ３Ｌ、ＴＧＦβおよびＲＡＮＫ−Ｌからなる群より選択され、そして免疫抑制抗体が、抗ＩＬ−２、抗ＩＬ−１２および抗ＩＦＮ−γからなる群より選択される、組成物。
- 微生物が、Lactobacillus、Leuconostoc、Pediococcus、Lactococcus、Streptococcus、Aerococcus、Carnobacterium、Enterococcus、Oenococcus、Teragenococcus、Vagococcus、WeisellaおよびSaccharomyces cerevisiaeからなる群より選択される、請求項１１記載の組成物。
- 免疫抑制サイトカインの産生を刺激する化合物、好ましくはコレラ毒素Ｂサブユニットをさらに含む、請求項１１または１２記載の組成物。
- 抗原および／または免疫モデュレーション化合物分泌微生物が、少なくとも１０フェムトグラムから１００mgの用量で存在する、請求項１１から１３のいずれか記載の組成物。
- 抗原に対する望まれない免疫反応により起こる疾患に関与する疾患もしくは障害を処置、予防および／もしくは緩和するための、または免疫寛容を誘導するための、少なくとも抗原を免疫モデュレーション化合物分泌微生物と組み合わせて含む薬剤、ニュートラシューティカルまたはメディカルフード。
- 抗原に対する望まれない免疫反応により起こる疾患がアレルギー反応、移植片対宿主病または薬物療法の免疫活性化である、請求項１または２記載の使用。
- 抗原に対する望まれない免疫反応により起こる疾患がアレルギー反応、移植片対宿主病または薬物療法の免疫活性化である、請求項１５記載の薬剤、ニュートラシューティカルまたはメディカルフード。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111467.6 | 2005-11-29 | ||
| EP05111467 | 2005-11-29 | ||
| PCT/EP2006/069062 WO2007063075A1 (en) | 2005-11-29 | 2006-11-29 | Induction of mucosal tolerance to antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013098504A Division JP2013189446A (ja) | 2005-11-29 | 2013-05-08 | 抗原に対する粘膜寛容の誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009521406A JP2009521406A (ja) | 2009-06-04 |
| JP2009521406A5 true JP2009521406A5 (ja) | 2010-01-14 |
| JP5410759B2 JP5410759B2 (ja) | 2014-02-05 |
Family
ID=37889980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542752A Expired - Fee Related JP5410759B2 (ja) | 2005-11-29 | 2006-11-29 | 抗原に対する粘膜寛容の誘導 |
| JP2013098504A Pending JP2013189446A (ja) | 2005-11-29 | 2013-05-08 | 抗原に対する粘膜寛容の誘導 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013098504A Pending JP2013189446A (ja) | 2005-11-29 | 2013-05-08 | 抗原に対する粘膜寛容の誘導 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US8748126B2 (ja) |
| EP (3) | EP1957100B1 (ja) |
| JP (2) | JP5410759B2 (ja) |
| CN (1) | CN101316611B (ja) |
| AU (1) | AU2006319216B2 (ja) |
| BR (1) | BRPI0619206A2 (ja) |
| CA (1) | CA2631598C (ja) |
| DK (1) | DK2119450T3 (ja) |
| ES (2) | ES2596855T3 (ja) |
| HK (1) | HK1231371A1 (ja) |
| PT (1) | PT2119450E (ja) |
| RU (1) | RU2420569C2 (ja) |
| WO (1) | WO2007063075A1 (ja) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7780961B2 (en) | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
| US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
| ES2596855T3 (es) | 2005-11-29 | 2017-01-12 | Intrexon Actobiotics Nv | Inducción de tolerancia mucosa a antígenos |
| EP2347775B1 (en) | 2005-12-13 | 2020-04-15 | President and Fellows of Harvard College | Scaffolds for cell transplantation |
| US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
| JP2010513245A (ja) * | 2006-12-14 | 2010-04-30 | アクトジェニックス・エヌブイ | 免疫調節を誘起するための結合分子の送達 |
| DK2774621T3 (en) * | 2007-01-25 | 2018-05-07 | Intrexon Actobiotics Nv | TREATMENT OF IMMUNE DISEASE BY MUCOSAL ADMINISTRATION OF ANTIGENS |
| US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
| FI20075539L (fi) * | 2007-07-12 | 2009-01-13 | Valio Oy | Maitohappobakteerit, joilla on proinflammatorisia ominaisuuksia |
| CA2715460C (en) | 2008-02-13 | 2020-02-18 | President And Fellows Of Harvard College | Continuous cell programming devices |
| US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
| US8821887B2 (en) | 2008-08-15 | 2014-09-02 | Circassia Limited | T-cell antigen peptide from allergen for stimulation of IL-10 production |
| DK2153841T4 (en) | 2008-08-15 | 2016-02-15 | Circassia Ltd | Vaccine comprising Amb a 1 peptides for use in the treatment of ambrosieallergi |
| WO2010056143A1 (en) * | 2008-11-13 | 2010-05-20 | Instituto De Medicina Molecular | The use of adjuvant to facilitate the induction of immune tolerance |
| WO2010089554A1 (en) | 2009-02-05 | 2010-08-12 | Circassia Limited | Peptides for vaccine |
| WO2011005850A1 (en) * | 2009-07-07 | 2011-01-13 | The Research Foundation Of State University Of New York | Lipidic compositions for induction of immune tolerance |
| US10617640B2 (en) | 2009-07-07 | 2020-04-14 | The Research Foundation For The State University Of New York | Phosphoserine containing compositions for immune tolerance induction |
| EP2461828B1 (en) * | 2009-07-31 | 2017-06-21 | President and Fellows of Harvard College | Programming of cells for tolerogenic therapies |
| US20110081320A1 (en) * | 2009-10-06 | 2011-04-07 | Nubiome, Inc. | Treatment/Cure of Autoimmune Disease |
| US20130058898A1 (en) | 2010-03-10 | 2013-03-07 | Kaneka Corporation | Lactic acid bacterium-containing preparation |
| WO2011150235A1 (en) * | 2010-05-27 | 2011-12-01 | Allertein Therapeutics, Llc | Methods and reagents for treating autoimmune disorders and/or graft rejection |
| DK2624873T3 (da) | 2010-10-06 | 2020-03-02 | Harvard College | Injicerbare, pore-dannende hydrogeler til materiale-baserede celleterapier |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| CA2833385C (en) | 2011-04-28 | 2020-10-27 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
| EP2714073B1 (en) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | In situ antigen-generating cancer vaccine |
| DK2758512T3 (en) | 2011-09-23 | 2018-07-23 | Intrexon Actobiotics Nv | MODIFIED GRAM POSITIVE BACTERIES AND APPLICATIONS THEREOF |
| WO2013041673A1 (en) | 2011-09-23 | 2013-03-28 | Actogenix Nv | Modified gram positive bacteria and uses thereof |
| CA2863532A1 (en) * | 2012-02-08 | 2013-08-15 | Premune Ab | Prevention of inflammatory disorders in domestic non-human mammals |
| CN104244929B (zh) | 2012-04-16 | 2017-04-05 | 哈佛学院董事会 | 用于调节免疫反应的介孔二氧化硅组合物 |
| DK2855667T3 (da) * | 2012-05-25 | 2023-10-30 | Cellectis | Fremgangsmåder til manipulation af allogeniske og immunosuppressiv-resistante T-celler til immunterapi |
| JP6219728B2 (ja) * | 2014-01-15 | 2017-10-25 | キッコーマン株式会社 | Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物 |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| NZ723879A (en) * | 2014-02-21 | 2018-03-23 | Ecole Polytechnique Fed Lausanne Epfl | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| JP7348708B2 (ja) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 組み合わせワクチン装置および癌細胞を殺滅する方法 |
| EP2989904A1 (en) * | 2014-07-29 | 2016-03-02 | Heinrich-Heine-Universität | Induction of immunological tolerance using yeast |
| KR101662898B1 (ko) * | 2014-09-02 | 2016-10-06 | 서울대학교산학협력단 | 점막점착성 고분자 및 이의 용도 |
| CN107208107B (zh) | 2014-12-23 | 2021-07-09 | 伊利亚制药公司 | 伤口愈合的方法 |
| US10363288B2 (en) | 2015-01-14 | 2019-07-30 | National Jewish Health | Insulin mimotopes and methods of using the same |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
| EP3081227A1 (en) * | 2015-04-15 | 2016-10-19 | Institut National De La Recherche Agronomique | Lactococcus lactis producing tslp or il-25 and their uses as probiotics and therapeutics |
| WO2017062175A1 (en) * | 2015-10-06 | 2017-04-13 | Albert Einstein College Of Medicine, Inc. | Microbial hyperswarmers and uses thereof |
| CN109072197A (zh) | 2016-02-06 | 2018-12-21 | 哈佛学院校长同事会 | 重塑造血巢以重建免疫 |
| AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| CA3035151A1 (en) | 2016-09-02 | 2018-03-08 | Intrexon Actobiotics N.V. | Genetically modified bacteria stably expressing il-10 and insulin |
| RU2762940C2 (ru) | 2016-09-13 | 2021-12-24 | Интрексон Актобиотикс Н.В. | Мукоадгезивный микроорганизм |
| CN108114272A (zh) * | 2016-11-28 | 2018-06-05 | 上海市第五人民医院 | 一种构建哮喘免疫耐受模型的方法 |
| CA3076014A1 (en) * | 2017-09-29 | 2019-04-04 | Nantcell, Inc. | Antigenic proteins and methods therefor |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| JP2020000033A (ja) * | 2018-06-26 | 2020-01-09 | 国立大学法人広島大学 | 経口免疫寛容誘導剤、これを含有する食品および医薬品、ならびに加工食品の製造方法 |
| US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CN110408579A (zh) * | 2019-06-03 | 2019-11-05 | 东北农业大学 | 牛白细胞介素-2重组乳酸菌及其应用 |
| CN114761028A (zh) | 2019-09-27 | 2022-07-15 | 英特瑞克斯顿阿克图比奥帝克斯有限公司 | 乳糜泻的治疗 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4100495A (en) | 1975-11-27 | 1978-07-11 | Cselt - Centro Studi E Laboratori Telecomunicazioni | Adaptive method of and means for recovering digital signals |
| US4190495A (en) | 1976-09-27 | 1980-02-26 | Research Corporation | Modified microorganisms and method of preparing and using same |
| US4874702A (en) | 1980-09-08 | 1989-10-17 | Biogen, Inc. | Vectors and methods for making such vectors and for expressive cloned genes |
| US4888170A (en) | 1981-10-22 | 1989-12-19 | Research Corporation | Vaccines obtained from antigenic gene products of recombinant genes |
| US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
| US5032510A (en) | 1984-09-26 | 1991-07-16 | Eli Lilly And Company | Method for expression and secretion in bacillus |
| IL76422A0 (en) | 1984-09-26 | 1986-01-31 | Lilly Co Eli | Method for expression and secretion in bacillus |
| EP0681026A1 (en) | 1987-03-02 | 1995-11-08 | Whitehead Institute For Biomedical Research | Recombinant mycobacterial vaccine |
| US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
| US5591632A (en) | 1987-03-02 | 1997-01-07 | Beth Israel Hospital | Recombinant BCG |
| US5330753A (en) | 1987-04-29 | 1994-07-19 | President And Fellows Of Harvard College | Cholera vaccines |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| US5972685A (en) | 1988-07-21 | 1999-10-26 | Iowa State University Research Foundation, Inc. | Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration |
| IE892131A1 (en) | 1989-06-30 | 1991-01-02 | Univ Cork | Marker genes for genetic manipulation |
| US5149532A (en) | 1989-11-01 | 1992-09-22 | Cedars Sinai Medical Center | Method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms |
| DE4006521A1 (de) | 1990-03-02 | 1991-09-05 | Bayer Ag | Zuckerhaltige polymere zur umhuellung und einbettung von arzneistoffen |
| GB9006400D0 (en) | 1990-03-22 | 1990-05-23 | Ciba Geigy Ag | Bacterial vectors |
| IL99097A0 (en) | 1990-09-05 | 1992-07-15 | Akzo Nv | Haemophilus paragallinarum vaccine |
| WO1992015689A1 (en) | 1991-03-05 | 1992-09-17 | The Wellcome Foundation Limited | Expression of recombinant proteins in attenuated bacteria |
| ATE216253T1 (de) | 1991-10-07 | 2002-05-15 | Brigham & Womens Hospital | Verfahren zur erhöhung der darmabsorption |
| IL103530A0 (en) | 1991-10-25 | 1993-03-15 | Duphar Int Res | Treponema hyodysenteriae vaccine |
| CA2130453A1 (en) | 1992-02-27 | 1993-09-02 | Richard W. F. Le Page | Heterologous gene expression in lactococcus, and the expression products threrefrom |
| US5455034A (en) | 1992-06-26 | 1995-10-03 | Kansas State University Research Foundation | Fusobacterium necrophorum leukotoxoid vaccine |
| DE4231764A1 (de) | 1992-09-23 | 1994-03-24 | Inst Pflanzengenetik & Kultur | Verfahren zur chromosomalen Integration eines Produkt-Gens |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US5691185A (en) | 1993-10-08 | 1997-11-25 | Chr. Hansen A/S | Lactic acid bacterial suppressor mutants and their use as selective markers and as means of containment in lactic acid bacteria |
| NZ274482A (en) | 1993-10-13 | 1997-09-22 | Gx Biosystems As | Cells transformed with a truncated and/or mutated staphylococcus aureus nuclease and their use in immunological, pesticidal and environmental pollutant-degrading compositions |
| IT1270123B (it) | 1994-10-05 | 1997-04-28 | Dompe Spa | Composizioni farmaceutiche contenenti microorganismi ingegnerizzati e loro uso per terapia |
| US5733540A (en) | 1995-03-08 | 1998-03-31 | Lee; Peter Poon-Hang | Protection from viral infection via colonization of mucosal membranes with genetically modified bacteria |
| AU2149495A (en) | 1995-04-11 | 1996-10-30 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface |
| US5753622A (en) | 1995-05-10 | 1998-05-19 | University Technologies International, Inc. | Use of epidermal growth factor as a gastrointestinal therapeutic agent |
| ATE312934T1 (de) | 1995-06-07 | 2005-12-15 | Univ Washington | Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit |
| US5824538A (en) | 1995-09-06 | 1998-10-20 | The United States Of America As Represented By The Secretary Of The Army | Shigella vector for delivering DNA to a mammalian cell |
| GB9518323D0 (en) | 1995-09-07 | 1995-11-08 | Steidler Lothar | Materials and methods relating to the attachment and display of substances on cell surfaces |
| GB9521568D0 (en) | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| EP0921816A4 (en) | 1996-03-28 | 2004-09-22 | Whitehead Biomedical Inst | CELLS WITH INCREASED OPSONINE CONTENT AND METHOD FOR REGULATING AN IMMUNE RESPONSE TO ANTIQUE |
| WO1997038688A1 (en) | 1996-04-12 | 1997-10-23 | Peptide Technology Pty. Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
| US6261561B1 (en) | 1996-04-19 | 2001-07-17 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens |
| US5972887A (en) | 1996-09-19 | 1999-10-26 | The Nemours Foundation | Treatment of intestinal epithelial cell malfunctions with Hepatocyte Growth Factor |
| US5723245A (en) | 1996-10-09 | 1998-03-03 | Xerox Corporation | Colored toner and developer compositions and process for enlarged color gamut |
| US7361331B2 (en) * | 1996-10-18 | 2008-04-22 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food | Plant bioreactors |
| GB9700939D0 (en) | 1997-01-17 | 1997-03-05 | Microbial Technics Limited | Therapy |
| US6685943B1 (en) | 1997-01-21 | 2004-02-03 | The Texas A&M University System | Fibronectin binding protein compositions and methods of use |
| EP0892054B1 (en) | 1997-06-20 | 2006-11-29 | Intervet International BV | Clostridium perfringens vaccine |
| US6100388A (en) | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
| WO1999058652A2 (en) | 1998-05-07 | 1999-11-18 | Gx Biosystems A/S | Cytotoxin-based biological containment |
| US6190669B1 (en) | 1998-05-13 | 2001-02-20 | University Of Maryland, Baltimore | Attenuated mutants of salmonella which constitutively express the Vi antigen |
| ES2234306T3 (es) | 1998-09-28 | 2005-06-16 | Warner-Lambert Company Llc | Administracion enterica y via colon usando capsulas de hpmc. |
| AU1071200A (en) | 1998-10-19 | 2000-05-08 | Biotech Australia Pty Limited | Systems for oral delivery |
| EP1123314B1 (en) | 1998-10-20 | 2004-02-18 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of a cytokine-producing lactococcus strain to treat colitis |
| PT1194554E (pt) | 1999-07-05 | 2007-01-31 | Vlaams Interuniv Inst Biotech | Libertação de péptidos trifólios |
| DK1356073T3 (da) | 2000-10-20 | 2010-04-06 | Bioneer As | Fermenteringsfremgangsmåde til fremstilling af heterologe genprodukter i mælkesyrebakterier |
| US7780961B2 (en) | 2001-05-03 | 2010-08-24 | Actogenix N.V. | Self-containing Lactococcus strain |
| WO2002090551A2 (en) | 2001-05-03 | 2002-11-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Self-containing lactococcus strain |
| NO318426B1 (no) | 2001-10-02 | 2005-04-18 | Neurozym Biotech As | Et materiale for a senke konsentrasjonen av patogene tarmpeptider |
| EP1319410A1 (en) | 2001-12-11 | 2003-06-18 | Société des Produits Nestlé S.A. | Use of micro-organisms for a directed delivery of substances to specific parts of the gut |
| US20040043003A1 (en) | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
| DE10208653A1 (de) * | 2002-02-28 | 2003-09-18 | Medinnova Ges Med Innovationen | Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren |
| US7425449B2 (en) | 2002-04-30 | 2008-09-16 | The Regents Of The University Of California | Site specific Listeria integration vectors and methods for using the same |
| US7605150B2 (en) | 2002-05-14 | 2009-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
| EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
| EP1513545B1 (en) | 2002-06-19 | 2008-03-19 | Actogenix N.V. | Methods and means to promote gut absorption |
| CA2506031A1 (en) | 2002-11-15 | 2004-06-03 | Vib Vzw | Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof |
| ES2383595T3 (es) | 2002-11-20 | 2012-06-22 | The Board Of Trustees Of The Leland Stanford Junior University | Procedimiento de diagnóstico de la celiaquía |
| JP4589618B2 (ja) * | 2003-11-28 | 2010-12-01 | 独立行政法人農業生物資源研究所 | 免疫調節性機能を誘導する乳酸菌類とその成分 |
| EP1725254A4 (en) * | 2004-02-04 | 2008-02-13 | Univ Columbia | ANTI-CD3 AND ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF AUTOIMMUNITY |
| CN1695469A (zh) | 2005-05-17 | 2005-11-16 | 田星 | 一种风味益生发酵乳及其制作方法 |
| ES2596855T3 (es) * | 2005-11-29 | 2017-01-12 | Intrexon Actobiotics Nv | Inducción de tolerancia mucosa a antígenos |
| DK2774621T3 (en) | 2007-01-25 | 2018-05-07 | Intrexon Actobiotics Nv | TREATMENT OF IMMUNE DISEASE BY MUCOSAL ADMINISTRATION OF ANTIGENS |
-
2006
- 2006-11-29 ES ES06830192.8T patent/ES2596855T3/es active Active
- 2006-11-29 JP JP2008542752A patent/JP5410759B2/ja not_active Expired - Fee Related
- 2006-11-29 EP EP06830192.8A patent/EP1957100B1/en not_active Not-in-force
- 2006-11-29 RU RU2008126198/10A patent/RU2420569C2/ru not_active IP Right Cessation
- 2006-11-29 ES ES09169276T patent/ES2405552T3/es active Active
- 2006-11-29 CA CA2631598A patent/CA2631598C/en active Active
- 2006-11-29 EP EP16178877.3A patent/EP3097924B1/en active Active
- 2006-11-29 BR BRPI0619206-8A patent/BRPI0619206A2/pt not_active Application Discontinuation
- 2006-11-29 AU AU2006319216A patent/AU2006319216B2/en not_active Ceased
- 2006-11-29 EP EP09169276A patent/EP2119450B1/en not_active Not-in-force
- 2006-11-29 WO PCT/EP2006/069062 patent/WO2007063075A1/en active Application Filing
- 2006-11-29 CN CN200680044662.2A patent/CN101316611B/zh not_active Expired - Fee Related
- 2006-11-29 DK DK09169276.4T patent/DK2119450T3/da active
- 2006-11-29 PT PT91692764T patent/PT2119450E/pt unknown
- 2006-11-29 US US12/094,384 patent/US8748126B2/en active Active
-
2009
- 2009-10-09 US US12/577,053 patent/US8398995B2/en active Active
-
2013
- 2013-05-08 JP JP2013098504A patent/JP2013189446A/ja active Pending
-
2014
- 2014-03-17 US US14/216,842 patent/US9526750B2/en active Active
- 2014-03-17 US US14/216,887 patent/US9539291B2/en active Active
-
2016
- 2016-10-21 US US15/331,020 patent/US10195269B2/en not_active Expired - Fee Related
-
2017
- 2017-05-17 HK HK17104938.8A patent/HK1231371A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009521406A5 (ja) | ||
| RU2008126198A (ru) | Индукция толерантности к антигенам через слизистую | |
| Hajavi et al. | The immunomodulatory role of probiotics in allergy therapy | |
| McGeachy et al. | Th17 cell differentiation: the long and winding road | |
| Coleman et al. | Alveolar macrophages contribute to respiratory tolerance by inducing FoxP3 expression in naive T cells | |
| Rachid et al. | The microbial origins of food allergy | |
| Zidek et al. | Current status and challenges of cytokine pharmacology | |
| JP2007514637A5 (ja) | ||
| Yu et al. | House dust mite allergy: environment evaluation and disease prevention | |
| Ye et al. | The treg/th17 imbalance in patients with obstructive sleep apnoea syndrome | |
| JP2014534957A5 (ja) | ||
| Takeda et al. | Antiallergic activity of probiotics from Mongolian dairy products on type I allergy in mice and mode of antiallergic action | |
| JP2012525346A5 (ja) | ||
| EP3213767A1 (en) | Antigen-specific induction of tolerance | |
| Zuercher et al. | Lactococcus lactis NCC 2287 alleviates food allergic manifestations in sensitized mice by reducing IL-13 expression specifically in the ileum | |
| Lee et al. | Effect of orally administered Lactobacillus brevis HY7401 in a food allergy mouse model | |
| Lee et al. | Immunomodulatory and anti-allergic effects of orally administered Lactobacillus species in ovalbumin-sensitized mice | |
| Bonnegarde-Bernard et al. | IKKβ in intestinal epithelial cells regulates allergen-specific IgA and allergic inflammation at distant mucosal sites | |
| Keet et al. | The year in food allergy | |
| Susanti et al. | Asthma clinical improvement and reduction in the number of CD4 CD25 foxp3 Treg and CD4 IL-10 cells after administration of immunotherapy house dust mite and adjuvant probiotics and/or Nigella Sativa powder in mild asthmatic children | |
| Ye et al. | Strategies of mucosal immunotherapy for allergic diseases | |
| US20140288159A1 (en) | Probiotic gram-positive bacteria for the prophylaxis, suppression, or elimination of allergic reactions in human | |
| CN110892914A (zh) | 副干酪乳杆菌k56改善气喘及相关过敏性症状的新应用 | |
| CN102281894A (zh) | 睡眠中呼吸努力相关觉醒和打鼾的治疗以及药剂 | |
| Behncke et al. | Azelastine nasal spray and fluticasone nasal spray in the treatment of geriatric patients with rhinitis |